Decera Clinical Education Oncology Podcast
A clinical education podcast covering new data and best practices in oncology, spanning a wide range of solid tumors and hematologic malignancies. Episodes are produced by Decera Clinical Education and offer practical clinical insights and treatment strategies for clinicians caring for patients with cancer. Selected episodes also provide CME/CE credit for listeners. The show is aimed at oncologists, hematologists, and other healthcare professionals seeking concise updates on emerging research and its application to practice.
Episodes
PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management
In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including:HRR alterations and the mechanism of action of PARP inhibito
Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma
Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAja
ASCO 2026 Updates in Metastatic Breast Cancer
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including:Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomesEmerging precision strategies in HR-
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape
In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cel
Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing
In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed A
ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negati
CELMoDs on the Horizon: A New Chapter in Lymphoma Care
Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas cov
Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including:
Treatment for underserved populations
Navigating REMS for novel therapeutics
Clinical trial design and enrolment
Presenters:Jesus G. Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Partner
Tennessee Onco
Experts Discuss CELMoD Agents for Multiple Myeloma
In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including:
The recent FDA approval of iberdomide
Mechanism of action and differentiation from IMiDs
Current data and potential treatment settings
Presenters:Meletios-Athanasios (Thanos) C. Dimopoulos, MD
Professor a
Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain
TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care
Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, chal
Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including:
Risk stratification and treatment selection for smoldering multiple myeloma
Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients
Clinical evidence supporting triplet a
New and Emerging Targeted Therapies for Patients With DLBCL
In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including:
Overview of Unmet Needs With Current Standard of Care in DLBCL
Expanding Role of Novel Agents in DLBCL
Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice
Key Ongoing Trials
Changing the Paradigm in HER2-Positive Early Breast Cancer
New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings.
Presenters:
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed C
Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma
Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice.
Presenters:Sagar Lonial, MD, FACP, FASCO
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chi
To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM
In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including:
Contemporary Risk Stratification
Interpreting Evidence for Early Intervention
Treatment vs Observation: Patient Selection
Treatment Selection and Sequencing Considerations
Safety, Moni
Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC
Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover:
The evolving role of TROP2-directed antibody-drug conjugate
Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM
In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including:
The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab
Neurologic toxicities like the clinical manifestation of ICANS
Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including:
The evolving role of chemotherapy
Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma
Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease
The potential impact of these developme
Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include:
Clinical trial updates and discussion of how findings
What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma
In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including:
A Brief Overview of BCMA in Multiple Myeloma
Advances in BCMA-Targeted Agents in P
Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer
Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer.
Presenters:
Cristina Saura Manich, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d'Hebron University Hospital
Breast Cancer Program, Vall d'Hebron
Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
Link to claim CME credit: https://bit.ly/4uRr3ir
In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including:
First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval
Adverse event identification and management
Generali
Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness
In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including:
Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages
Updated screening guidelines that have expanded eligibility
Key challenges that impact screening participat
HNSCC: Current and Emerging Therapeutic Strategies
In this episode, Aarti Bhatia, MD, MPH, and Deborah J. Wong, MD, PhD, discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, an
Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies
In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including:
Practical differences among approved bispecific antibodies
Toxicity profiles of approved bispecific antibodies
When to refer patients for evaluation for immunotherapies
Considerations for sequencing bispecific antibodies in the relapsed/refractory set
Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma
In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies.
Presenters:
Muhamed Baljevic, MD, FACP
Associate Professor of Medicine
Division o
Thrombotic Events and ET/PV: What You Should Know
In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis:
PV and ET increase the risk of both arterial and venous thrombotic events
Unusual thrombotic events
Thrombosis as initial presentation for MPN
Case presentations
Brief overview of thrombosi
Global Experts Discuss Current and Emerging Treatments for ET and PV
In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following:
Overview of current treatment paradigms for PV and ET
Importance of shared decision-making and patient communication in determining treatment
Current th
Global Experts Discuss Diagnostic Considerations in ET and PV
In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including:
Overview of diagnostic criteria for PV and ET
Importance of bone marrow biopsy
Degree of suspicion of PV/ET in patients presenting with thrombotic events
Pearls of wisdom in diagnosis
Presenter
Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer
In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following:
Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09
Adding palbociclib to HP and ET as maintenance therap
Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes
A patient advocate/cancer survivor and a healthcare professional discuss key topics including early breast cancer diagnosis, role of self-agency in pursuing optimal cancer care, encouraging trial participation with patient testimonials, and other considerations for the patient care journey such as appropriate screening, follow-up encounters for questions, guideline-based treatments, and side effec
Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices.
Presenters:
Nadia Harbeck, MD
Breast Cancer Director
Department of OB&GYN and Comprehensive Cancer Center Munich
LMU University Hospital
Munich, Germany
Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including:
Practical strategies for monitoring and managing key adverse events associated with
TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions
In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including
The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan
Use of these therapies in EG
Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including:
A brief overview of BTC and GEA
Notable findings from a recent survey of healthcare professionals on BTC and GEA
Case studies on recommended management of patients
Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC
In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:
Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important
ADCs for HER2-negative/ultralow/low MBC
Patient communication: best practices in discussing treatment goals and potential AEs
Presenter
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer
Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of pa
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer
Listen to this audio podcast covering biomarker testing in patients with prostate cancer. Learn from Sara Traverso, MMS, PA-C, and Brenda Martone, MSN, ANP-BC, AOCNP, about when to conduct germline and somatic genetic testing in patients with prostate cancer, discussing testing with patients and their caregivers, recognizing actionable biomarkers, and improving APP confidence in the application of
Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026
In this episode, Sam S. Chang, MD, MBA, and Matthew D. Galsky, MD, discuss the rapidly evolving treatment landscape in bladder cancer, highlighting new therapeutic options, emerging clinical trial data, including the latest results presented at ASCO GU 2026, and the growing role of biomarkers and multidisciplinary care, including:
New treatment options for BCG-unresponsive non–muscle-invasive bl
Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization
In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.
Presenters:
Rodney Hunter, PharmD, BCOP
Director of Clinical S
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including:
How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe
Practical sequen
2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast
Listen to learn from Sara M. Tolaney, MD, MPH, and Virginia Kaklamani, MD, DSc,
about new clinical trial data and updates informing the care of patients with early breast cancer and locally advanced/metastatic breast cancer that were presented at the 2025 San Antonio Breast Cancer Symposium.
Presenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
As
Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions
In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:
Clinical outcomes and limitations of first-generation KRAS G12C inhibitors
Key unmet needs, including primary and acquired resistance
Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and
Beyond Chemotherapy in ALL: Emerging Bispecific Antibodies, CAR T-cell Therapies, and Evolving Treatment Strategies
In this episode, Dr Ibrahim Aldoss and Dr Bijal Shah discuss how immunotherapy has transformed the treatment landscape of acute lymphoblastic leukemia (ALL), particularly in relapsed/refractory B-cell ALL, including:
CD19-directed CAR T-cell therapies
Next-generation CD19 bispecific antibodies
The evolving role of allogeneic transplant
Presenters:
Ibrahim Aldoss, MD
Associate Professor
Divi
Experts Discuss Novel RAS-Targeted Therapy for Pancreatic Cancer
In this podcast episode, Nilofer Azad, MD, FASCO, and Zev A. Wainberg, MD, discuss novel RAS-targeted therapies for pancreatic cancer, including the following:
Optimal KRAS mutation testing
Emerging multiselective RAS inhibitors
Combination strategies
Presenters:
Nilofer Azad, MD, FASCO
Professor of Oncology
Associate Director of Clinical Research
Sidney Kimmel Cancer Center at Johns Hopk
Advanced Practice Professionals Discuss Biomarker Testing in Patients With Solid Tumors: Lung Cancer
Advanced practice providers discuss biomarker testing in patients with lung cancer. Listen in to learn from Beth Sandy, MSN, CRNP,FAPO, and Denise Rouse, MS, PA-C, about key biomarker testing in patients with lung cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker testing in patients wit
Individualized Hemophilia Care With Hemostatic Rebalancing Therapies
In this podcast episode, experts Angela Weyand and Guy Young discuss their experience using hemostatic rebalancing agents for prophylaxis in patients diagnosed with hemophilia. Three rebalancing agents have now been approved, including concizumab, fitusiran, and marstacimab. These new rebalancing agents target the body's natural anticoagulants and provide individualized, convenient options for pat
Experts Offer Guidance on Shared Decision-making in the Management of Patients With PV/ET
In this episode, hear Joan How, MD and Pankit Vachhani, MD share their insights on the importance of shared decision-making (SDM) for patients with polycythemia vera (PV) or essential thrombocythemia (ET) including: Personal insights and examples of the process of SDM with patients with PV or ETHow nuances of managing PV/ET influence SDMIndividualizing the process of SDMBarriers to effective SDMEd
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive
Experts Discuss CELMoD Agents for Treating Multiple Myeloma
In this podcast episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Niels van de Donk, MD, PhD, address key questions on CELMoD agent therapy for multiple myeloma, including:Combination strategiesAdverse event managementWhere CELMoD agents may best fit within current and future treatment strategies Presenters: Jesus Berdeja, MDDirector of Multiple Myeloma ResearchGreco-Hainsworth Centers fo
Expert Highlights From the 2025 World Conference on Lung Cancer
In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett J
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting
In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM RedirecTT-1: Updated efficacy and safety of talquetamab +
PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:CLL17: randomized phase III trial of continuous ibrutinib vs
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients
PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fi
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?
In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLCTIGIT-targeting agents: domvanalimab, rilvegostomigPresenters:Benjamin Levy, MD,
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer
In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including:Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selectionThe recently approved targeted therapy combination regimen
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancerResults of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant diseaseHow R-DXd may be incorporated into th
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care
In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including:Trials of neoadjuvant immunotherapies demonstrating remarkable response rates with PD-(L)1 inhibitors such as cemiplimab,
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clini
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer
In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on how to personalize adjuvant therapy for these patie
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer
In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare professional questions on how to personalize therapy
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including:Brief overview of BTC and GEAApproved HER2-directed therapies for BTC and GEA and their mechanisms of actionEfficacy and toxicities of the approved agents and
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma
In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the standard of care for patients with follicular lymp
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients
Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including:How patients often present with disease-related symptomsTreatment selection considerations for the first-line and second-line settingHow to approach palliative care discussions with patientsEmerging therapies that are showing promise in
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma
In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently under development for multiple myeloma.LymphomasDLB
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:Genomic testing options for assessing risk of recurrenceAdjuvant treatment duration and holidays with CDK4/6 inhibitorsManaging renal toxicities, prophylaxis for DVT, and a
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas
In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:The clinical implications of using DLL3 as a therapeutic targetThe impact of emerging DLL3-targeted therapies on evolving treatment paradigmsHow to incorporate DLL3-based treatments into clinical practicePrese
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective
In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedulesAvailable pharmacodynamics/pharmacokinetics, efficacy, an
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025
In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting
In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic breast cancerASCENT-04/KEYNOTE-D19: phase III trial of
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerIntera
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors?
In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care.Presenters:Eytan M. Stein, MDChief, Leukemia ServiceDirector, Program for Drug Development in LeukemiaAssociate Attending PhysicianLeukemia Service, Department of MedicineMemoria
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025
In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including:The randomized phase III FLAIR trialThe randomized phase III SEQUOIA trialThe randomized phase III BRUIN CLL-321 trial Presenters:James Davis, PharmD, BCOPClinical Pharmacy Spe
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma
In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCCOverview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies
In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 2025.The Landscape of Frontline Options in HLSpecial
Experts Discuss CELMoDs in Myeloma
In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDsEmerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myelomaThe clinical implications of MRD negativity as a surrogate marker of long-t
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities
In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of Polypha
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers.Toxicity Profiles of HER2-Targeted ADCs: Common and serious adverse events such as ILD/pneumonitis, ne
Recommended
K-Drama Obsessed Mamas | Beyond “Just One More Episode!”
True Crime Classics
The Healer Revolution
Becoming: HER with Nikki Spoelstra
Booked, Blonde & Busy w/ Olivia Ponton
McKinsey on Consumer and Retail
megahired.com
Hard Knocks Podcast
Effective Weight Loss for Moms | High protein, Strength Training, Lose Weight, Meal Planning, Fat Loss, Healthy Habits
The Human-Animal Connection - Pet Life Radio Original
Infinite Health with Dr. Arasi Maran
The Daily
